CAR-NK cell therapy for CD7-positive blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR-NK) that targets a protein called CD7 found on some leukemia and lymphoma cells. It may help people whose cancer has not responded to other treatments or has returned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer is CD7-positive and has come back or not responded to standard treatments.
- You are expected to live at least 12 weeks and are generally able to care for yourself (ECOG 0-2).
- Your liver, kidney, and heart function are within acceptable levels.
- You have not had CAR-T or CAR-NK therapy before, and you do not have active, uncontrolled infections.
- You are willing to sign a consent form and can follow the study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immune cell treatment (CAR-NK cells) targeting a protein called CD70 found on cancer cells. It's for people with T cell lymphoma or acute myeloid leukemia that has come back or not responded to other treatments.
This trial tests a new immune cell therapy (CD7 CAR-T) given as a bridge to a stem cell transplant in people with relapsed or hard-to-treat CD7-positive leukemia. The goal is to help control the leukemia and improve chances for a successful transplant.
This study tests a new type of immune cell therapy for people whose cancer cells have a specific marker called CD7. The treatment uses modified immune cells (CAR T-cells) to find and attack the cancer. It might help if other treatments haven't worked or the cancer has returned.
This early-stage trial tests a special immune cell treatment that targets a marker called CD7 on cancer cells, aiming to attack and destroy the cancer. It's designed for patients with blood cancers that express CD7 and who haven't had prior gene therapy.
This trial tests a new treatment using your own immune cells that are modified to find and attack cancer cells with a marker called CD7. It is for people with certain types of leukemia or lymphoma that have come back or not responded to standard treatments.
This trial tests a new treatment using specially engineered immune cells (CAR-NK cells) that are designed to find and destroy leukemia cells. It may be an option for patients whose leukemia has come back or hasn't responded to other treatments.
Hear when a new Immunology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.